Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus

Adam Levinson, Eli A. Nagler, Franklin C. Lowe

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

To evaluate the approach to management of localized prostate cancer (PCa) in patients with human immunodeficiency virus (HIV) in the highly active antiretroviral therapy era. A retrospective analysis was performed on 10 HIV-positive patients who recently presented with elevated prostate-specific antigen levels and clinically localized PCa. At the diagnosis of PCa, the average patient was 54.0 years old, had been HIV positive for 8.75 years, had a CD4 count of 417, a prostate-specific antigen level of 9.2 ng/mL, and a Gleason score of 6. Eight of the patients had risk factors for PCa - either African-American descent (n = 6) or a positive family history (n = 2). The treatment was laparoscopic radical prostatectomy in 1, potency-preserving androgen deprivation in 1, cryosurgery in 1, brachytherapy in 2, observation in 2, and external beam radiotherapy in 3. Screening of all HIV-positive men should be initiated at age 40 if they have either a positive family history of prostate cancer or are of African-American descent. Asymptomatic HIV-positive patients should be offered all therapeutic PCa treatment options.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalUrology
Volume65
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Prostatic Neoplasms
HIV
Prostate-Specific Antigen
African Americans
Cryosurgery
Neoplasm Grading
Highly Active Antiretroviral Therapy
Brachytherapy
CD4 Lymphocyte Count
Prostatectomy
Androgens
Radiotherapy
Therapeutics
Observation

ASJC Scopus subject areas

  • Urology

Cite this

Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. / Levinson, Adam; Nagler, Eli A.; Lowe, Franklin C.

In: Urology, Vol. 65, No. 1, 01.2005, p. 91-94.

Research output: Contribution to journalArticle

@article{3491222bbd6141cab2c142c4b4c4b7d7,
title = "Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus",
abstract = "To evaluate the approach to management of localized prostate cancer (PCa) in patients with human immunodeficiency virus (HIV) in the highly active antiretroviral therapy era. A retrospective analysis was performed on 10 HIV-positive patients who recently presented with elevated prostate-specific antigen levels and clinically localized PCa. At the diagnosis of PCa, the average patient was 54.0 years old, had been HIV positive for 8.75 years, had a CD4 count of 417, a prostate-specific antigen level of 9.2 ng/mL, and a Gleason score of 6. Eight of the patients had risk factors for PCa - either African-American descent (n = 6) or a positive family history (n = 2). The treatment was laparoscopic radical prostatectomy in 1, potency-preserving androgen deprivation in 1, cryosurgery in 1, brachytherapy in 2, observation in 2, and external beam radiotherapy in 3. Screening of all HIV-positive men should be initiated at age 40 if they have either a positive family history of prostate cancer or are of African-American descent. Asymptomatic HIV-positive patients should be offered all therapeutic PCa treatment options.",
author = "Adam Levinson and Nagler, {Eli A.} and Lowe, {Franklin C.}",
year = "2005",
month = "1",
doi = "10.1016/j.urology.2004.08.053",
language = "English (US)",
volume = "65",
pages = "91--94",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus

AU - Levinson, Adam

AU - Nagler, Eli A.

AU - Lowe, Franklin C.

PY - 2005/1

Y1 - 2005/1

N2 - To evaluate the approach to management of localized prostate cancer (PCa) in patients with human immunodeficiency virus (HIV) in the highly active antiretroviral therapy era. A retrospective analysis was performed on 10 HIV-positive patients who recently presented with elevated prostate-specific antigen levels and clinically localized PCa. At the diagnosis of PCa, the average patient was 54.0 years old, had been HIV positive for 8.75 years, had a CD4 count of 417, a prostate-specific antigen level of 9.2 ng/mL, and a Gleason score of 6. Eight of the patients had risk factors for PCa - either African-American descent (n = 6) or a positive family history (n = 2). The treatment was laparoscopic radical prostatectomy in 1, potency-preserving androgen deprivation in 1, cryosurgery in 1, brachytherapy in 2, observation in 2, and external beam radiotherapy in 3. Screening of all HIV-positive men should be initiated at age 40 if they have either a positive family history of prostate cancer or are of African-American descent. Asymptomatic HIV-positive patients should be offered all therapeutic PCa treatment options.

AB - To evaluate the approach to management of localized prostate cancer (PCa) in patients with human immunodeficiency virus (HIV) in the highly active antiretroviral therapy era. A retrospective analysis was performed on 10 HIV-positive patients who recently presented with elevated prostate-specific antigen levels and clinically localized PCa. At the diagnosis of PCa, the average patient was 54.0 years old, had been HIV positive for 8.75 years, had a CD4 count of 417, a prostate-specific antigen level of 9.2 ng/mL, and a Gleason score of 6. Eight of the patients had risk factors for PCa - either African-American descent (n = 6) or a positive family history (n = 2). The treatment was laparoscopic radical prostatectomy in 1, potency-preserving androgen deprivation in 1, cryosurgery in 1, brachytherapy in 2, observation in 2, and external beam radiotherapy in 3. Screening of all HIV-positive men should be initiated at age 40 if they have either a positive family history of prostate cancer or are of African-American descent. Asymptomatic HIV-positive patients should be offered all therapeutic PCa treatment options.

UR - http://www.scopus.com/inward/record.url?scp=12844250556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844250556&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.08.053

DO - 10.1016/j.urology.2004.08.053

M3 - Article

VL - 65

SP - 91

EP - 94

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -